Get started
Author

Qiangsheng Zhang

Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2
2021 · Zhihao Liu, Xi Hu, et al. · Journal of Medicinal Chemistry · 126
The molecular mechanisms of MLKL-dependent and MLKL-independent necrosis
2020 · Lu Li, An Tong, et al. · Journal of Molecular Cell Biology · 68
PDF
Recent developments in the catalytic conversion of cellulose
2014 · Yan Wang, Hang Song, et al. · Biotechnology & Biotechnological Equipment · 49
PDF
Discovery of a Novel Covalent EZH2 Inhibitor Based on Tazemetostat Scaffold for the Treatment of Ovarian Cancer
2023 · Qiangsheng Zhang, Xinyi Chen, et al. · Journal of Medicinal Chemistry · 36
Design and Synthesis of Fibroblast Growth Factor Receptor (FGFR) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Cancer
2022 · Guoquan Wan, Zhanzhan Feng, et al. · Journal of Medicinal Chemistry · 32
Covalent inhibitors of EZH2: Design, synthesis and evaluation
2022 · Qiangsheng Zhang, Xinyi Chen, et al. · Biomedicine & Pharmacotherapy · 26
PDF
Thioridazine hydrochloride: an antipsychotic agent that inhibits tumor growth and lung metastasis in triple-negative breast cancer via inducing G0/G1 arrest and apoptosis
2020 · Yanlin Song, Lu Li, et al. · Cell Cycle · 23
The discovery of SKLB-0335 as a paralog-selective EZH2 covalent inhibitor
2021 · Qiangsheng Zhang, Xi Hu, et al. · Chemical Communications · 21
Focus on the classical and non-classical functions of EZH2: Guide the development of inhibitors and degraders
2022 · Qiangsheng Zhang, Hongling Yang, et al. · Pharmacological Research · 19
Design, Synthesis and Evaluation of Antitumor Activity of Selective PRMT6 Inhibitors
2022 · Qiangsheng Zhang, Jiaying Cao, et al. · European Journal of Medicinal Chemistry · 19
Design and synthesis of (E)-1,2-diphenylethene-based EZH2 inhibitors
2020 · Hualong He, Xi Hu, et al. · Bioorganic & Medicinal Chemistry Letters · 18
Discovery of 3-(((9H-purin-6-yl)amino)methyl)-4,6-dimethylpyridin-2(1H)-one derivatives as novel tubulin polymerization inhibitors for treatment of cancer
2019 · Qiangsheng Zhang, Xi Hu, et al. · European Journal of Medicinal Chemistry · 18
Design, synthesis and antitumor activity of a novel FGFR2-selective degrader to overcome resistance of the FGFR2V564F gatekeeper mutation based on a pan-FGFR inhibitor
2024 · Zuli Hu, Qiangsheng Zhang, et al. · European Journal of Medicinal Chemistry · 16
Design, synthesis and biological evaluation of a novel tubulin inhibitor SKLB0565 targeting the colchicine binding site
2020 · Xi Hu, Lu Li, et al. · Bioorganic Chemistry · 14
PDF
Discovery of novel G9a/GLP covalent inhibitors for the treatment of triple-negative breast cancer
2023 · Qiangsheng Zhang, Bo Chang, et al. · European Journal of Medicinal Chemistry · 13
Design, synthesis and biological evaluation of indazole derivatives as selective covalent inhibitors of FGFR4 in wild-type and gatekeeper mutants
2023 · Yingyue Yang, Xiaojie He, et al. · European Journal of Medicinal Chemistry · 13
A patent review of EZH2 inhibitors from 2017 and beyond
2023 · Guoquan Wan, Huan Feng, et al. · Expert Opinion on Therapeutic Patents · 12
Synthesis and biological evaluation of benzomorpholine derivatives as novel EZH2 inhibitors for anti-non-small cell lung cancer activity
2019 · Qiang Feng, Hualong He, et al. · Molecular Diversity · 12
Pharmacological inhibition of EZH2 by ZLD1039 suppresses tumor growth and pulmonary metastasis in melanoma cells in vitro and in vivo
2023 · Yongxia Zhu, Lidan Zhang, et al. · Biochemical Pharmacology · 10
Discovery of a first-in-class degrader for the protein arginine methyltransferase 6 (PRMT6)
2024 · Hongling Yang, Qiangsheng Zhang, et al. · Bioorganic Chemistry · 9
Targeting type I PRMTs as promising targets for the treatment of pulmonary disorders: Asthma, COPD, lung cancer, PF, and PH
2024 · Shuyan Zhou, Qiangsheng Zhang, et al. · Life Sciences · 7
An updated patent review of EZH2 inhibitors (2024–present)
2025 · Guoquan Wan, Siyan Li, et al. · Expert Opinion on Therapeutic Patents · 5
Small molecule compounds targeting G9a/GLP: Recent advances and perspectives
2025 · Qiangsheng Zhang, Lu Li, et al. · European Journal of Medicinal Chemistry · 5
Covalent inhibitors meet epigenetics: New opportunities
2024 · Qiang Feng, Luoting Yu, et al. · European Journal of Medicinal Chemistry · 5
Discovery of novel indazole derivatives as type Ⅰ PRMTs inhibitors for the treatment of triple-negative breast cancer
2025 · Qiangsheng Zhang, Shuyan Zhou, et al. · European Journal of Medicinal Chemistry · 4
Works count: 42
Citation count: 595
H-index: 14
I10-index: 19
Year
Topic
Type